UK's MHRA says that the UK will not require additional approval route for devices already approved by the EU

UK's MHRA says that the UK will not require additional approval route for devices already approved by the EU.

Post-Brexit device regulation has followed a repeated pattern of the UK setting out a standalone domestic framework and then softening or delaying it, with recognition of EU approvals extended in stages rather than allowed to lapse into a hard dual-registration requirement. This announcement fits that trajectory: the direction of travel has consistently been toward continued reliance on EU conformity assessment as a route into the UK market, reflecting the practical reality that the UK is a small share of global device sales and manufacturers have limited appetite for a separate approval process. The operative distinction is between indefinite recognition and a time-limited bridging arrangement, since prior episodes in this file have tended to convert fixed deadlines into rolling or extended ones as they approached. Worth noting is what the statement does not settle: the status of devices not EU-approved, the future of the standalone domestic route, and any conditions attached to reliance such as post-market surveillance or registration requirements. The transmission channel into listed names runs through medtech and diagnostics supply chains rather than broad indices, and historically moves on such regulatory-continuity headlines have been modest and confined to the relevant subsector. The follow-ons are the formal legislative or guidance instruments implementing the policy and any EU-side response on reciprocity.